Table 3 Subgroup analysis of results by number of drugs and status of patients with COVID-19 after treatment
Subgroup | N | Sample size | Heterogeneity (I2) | Egger test | Prevalence (95% CI) | |
|---|---|---|---|---|---|---|
Polypharmacy by drug number | 4–9 | 5 | 35,788 | 98.5 | 0.631 | 26.8 (95% CI: 18.5–37.1) |
 > 10 | 6 | 99,416 | 99.8 | 0.751 | 17.1 (95% CI: 11.6–24.3) | |
Patient status after treatment | Survivors | 9 | 5490 | 98.2 | 0.144 | 42.1 (95% CI: 28.9–56.6) |
Non-survivors | 9 | 1508 | 88.3 | 0.972 | 54.8 (95% CI: 45.4–63.9) | |